Autologous transplantation with circulating stem cells : When to collect stem cells?

Bernard, P; Vezon, G; Sarrat, A.; Marit, Gérald; David, B.; Broustet, A

doi:10.1016/0145-2126(86)90205-5

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence autologous or major histocompatibility complexmatched bone marrow transplantation is the usual therapeutic vehicle for hematopoietic reconstitution. Although adult blood has had some use as an alternative source (5), in practice the content of stem/progenitor cells is so low (1,2) that multiple leukopheresis is necessary and has been reported primarily in patients undergoing intense temporary rebound hematopoiesis resulting from recent chemotherapy (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17).…”

mentioning

confidence: 99%

Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.

Broxmeyer

Douglas

Hangoc

et al. 1989

Proc. Natl. Acad. Sci. U.S.A.

1,075

538

View full text Add to dashboard Cite

The purpose of this study was to evaluate human umbilical cord blood as an alternative to bone marrow in the provision of transplantable stem/progenitor cells for hematopoietic reconstitution. Although no direct quantitative assay for human hematopoietic repopulating cells is at present available, the granulocyte-macrophage progenitor cell (CFU-GM) assay has been used with success as a valid indicator of engrafting capability. We examined greater than 100 collections of human umbilical cord blood for their content of nucleated cells and granulocyte-macrophage, erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells, in many cases both before and after cryopreservation. First it was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition of anticoagulant for at least 3 days at 4 degrees C or 25 degrees C (room temperature), though not at 37 degrees C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy after transport of cord blood by overnight air freight carriage from a remote obstetrical service. Granulocyte-macrophage progenitor cells from cord blood so received responded normally to stimulation by purified recombinant preparations of granulocyte-macrophage, granulocyte, and macrophage colony-stimulating factors and interleukin 3. The salient finding, based on analysis of 101 cord blood collections, is that the numbers of progenitor cells present in the low-density (less than 1.077 gm/ml) fraction after Ficoll/Hypaque separation typically fell within the range that has been reported for successful engraftment by bone marrow cells. Another observation of practical importance is that procedures to remove erythrocytes or granulocytes prior to freezing, and washing of thawed cells before plating, entailed large losses of progenitor cells, the yield of unwashed progenitor cells from unfractionated cord blood being many times greater. The provisional inference is that human umbilical cord blood from a single individual is typically a sufficient source of cells for autologous (syngeneic) and for major histocompatibility complex-matched allogeneic hematopoietic reconstitution.

show abstract

mentioning

confidence: 99%

Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.

Broxmeyer

Douglas

Hangoc

et al. 1989

Proc. Natl. Acad. Sci. U.S.A.

1,075

538

View full text Add to dashboard Cite

show abstract

“…Autopsy showed tumor in the bone marrow. Three patients have been reported with acute myelogenous leukemia (AML) in relapse, who were grafted with circulating stem cells collected in the early recovery phase following consolidation treatment [65,66]. The first patient received 1.3 x 10' nucleated cells/kg, with a GM-CFC of 29 X 104/kg.…”

Section: Clinical Studies In Malignant Diseases Other Than CMLmentioning

confidence: 99%

Autologous transplantation with circulating hemopoietic stem cells

Zander¹,

Cockerill²

1987

J of Clinical Apheresis

View full text Add to dashboard Cite

Circulating stem cells exist in sufficient numbers in mouse, dog, and man to allow collection and transplantation after ablative treatment. Preclinical studies in the mouse have shown a low concentration, with a transplantation potential ratio of bone marrow to blood of 1:100. The ratio of circulating stem cells to bone marrow stem cells is more favorable in the dog (1:10-20). Recent pilot studies carried out in different centers with 10 patients have shown that this approach is feasible in man, too. It appears that 5 X 10(8) mononuclear cells/kg of body weight collected by seven or eight leukapheresis procedures of about 4 hrs each is sufficient for fast hemopoietic recovery after marrow ablative treatment. Potential advantages of the use of blood stem cells over bone marrow stem cells are the decreased likelihood of contamination with malignant cells, the avoidance of general anesthesia, and the infusion of immunocompetent cells, which might hasten immunorecovery in the autologous setting.

show abstract

Collection of Circulating Haemopoietic Cells After Chemotherapy in Acute Non‐lymphocytic Leukaemia

et al. 1985

View full text Add to dashboard Cite

Autologous transplantation with circulating stem cells : When to collect stem cells?

Cited by 3 publications

References 0 publications

Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.

Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.

Autologous transplantation with circulating hemopoietic stem cells

Collection of Circulating Haemopoietic Cells After Chemotherapy in Acute Non‐lymphocytic Leukaemia

Contact Info

Product

Resources

About